Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 14;15(22):5404.
doi: 10.3390/cancers15225404.

Stereotactic Radiosurgery of Multiple Brain Metastases: A Review of Treatment Techniques

Affiliations
Review

Stereotactic Radiosurgery of Multiple Brain Metastases: A Review of Treatment Techniques

Raphael Bodensohn et al. Cancers (Basel). .

Abstract

The advancement of systemic targeted treatments has led to improvements in the management of metastatic disease, particularly in terms of survival outcomes. However, brain metastases remain less responsive to systemic therapies, underscoring the significance of local interventions for comprehensive disease control. Over the past years, the threshold for treating brain metastases through stereotactic radiosurgery has risen. Yet, as the number of treated metastases increases, treatment complexity and duration also escalate. This trend has made multi-isocenter radiosurgery treatments, such as those with the Gamma Knife, challenging to plan and lengthy for patients. In contrast, single-isocenter approaches employing linear accelerators offer an efficient and expeditious treatment option. This review delves into the literature, comparing different linear-accelerator-based techniques with each other and in relation to dedicated systems, focusing on dosimetric considerations and feasibility.

Keywords: brain metastases; dynamic conformal arc therapy (DCAT); single isocenter; stereotactic radiosurgery; volumetric arc therapy (VMAT).

PubMed Disclaimer

Conflict of interest statement

M.N. received speaker honoraria from Brainlab that did not affect the current work. R.B., S.H.M., C.B. and G.M. declare that they have no competing interests.

Figures

Figure 1
Figure 1
A relative comparison between the different treatment techniques; GK—Gamma Knife; SI-DCAT—single-isocenter dynamic arc therapy; SI-VMAT—single-isocenter volumetric arc therapy.

Similar articles

Cited by

References

    1. Hodi F.S., O’Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010;363:711–723. doi: 10.1056/NEJMoa1003466. - DOI - PMC - PubMed
    1. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel J.C., Rutkowski P., McNeil C., Kalinka-Warzocha E., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015;372:320–330. doi: 10.1056/NEJMoa1412082. - DOI - PubMed
    1. Robert C., Schachter J., Long G.V., Arance A., Grob J.J., Mortier L., Daud A., Carlino M.S., McNeil C., Lotem M., et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N. Engl. J. Med. 2015;372:2521–2532. doi: 10.1056/NEJMoa1503093. - DOI - PubMed
    1. Amaral T., Kiecker F., Schaefer S., Stege H., Kaehler K., Terheyden P., Gesierich A., Gutzmer R., Haferkamp S., Uttikal J., et al. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: A DeCOG* study in 380 patients. J. Immunother. Cancer. 2020;8:e000333. doi: 10.1136/jitc-2019-000333. - DOI - PMC - PubMed
    1. Theurich S., Rothschild S.I., Hoffmann M., Fabri M., Sommer A., Garcia-Marquez M., Thelen M., Schill C., Merki R., Schmid T., et al. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. Cancer Immunol. Res. 2016;4:744–754. doi: 10.1158/2326-6066.CIR-15-0156. - DOI - PubMed

LinkOut - more resources